

WEARABLES UPDATE FROM THE CEO OF CARDIEX, CRAIG COOPER

CARDIEX SUCCESSFULLY COMPLETES WORLD'S FIRST MEDICALLY RELIABLE WEARABLE SENSOR TECHNOLOGY.

24 April, 2020

CardieX Limited's (ASX: CDX) (CardieX, the Company) 100% subsidiary ATCOR has this week completed a **world first** engineering & technology feat in being the first company globally to derive unique and **medically reliable** heart and arterial health features from a PPG sensor.

Highlights

- Significant milestone towards FDA clearance for clinical and consumer applications for the sensor technology.
- Breakthrough will assist in effective remote diagnosis and monitoring of hypertension and cardiovascular disease which is a key complication for Coronaviruses such as COVID-19.
- Remote patient monitoring through wearable sensor technology would satisfy US FDA guidelines for remote monitoring of patients during COVID based on March 2020 guidelines issued by the FDA.
- Results to be presented this week to ATCOR wearables partner Mobvoi, the largest Googlebacked official Wear OS partner in Chinese market.
- Completion of development and associated algorithms satisfies Phase 1 of the Joint Development Agreement between Mobvoi and ATCOR.
- ATCOR has also been requested to demonstrate results to several major consumer wearable & technology companies.

PPG sensors are one of the most widely used optical sensor arrays on wearable devices consisting of LEDs and photodetectors. Most PPG sensors are used to create consumer-grade capabilities, such as heart rate measurement and other general fitness features. They are usually represented by a combination of red, green, and infrared light diodes on wearables and smart watches. Through internal human studies, and in conjunction with Macquarie University, ATCOR has been able to demonstrate specific heart and arterial health

features through multiple PPG sensor colour spectrums, leveraging proprietary IP on the foundation of its gold standard SphygmoCor® algorithms. This represents a significant milestone on the path towards eventual FDA clearance for these features for use in both clinical and consumer applications.

This development is especially important given that ATCOR's heart and arterial health features have specific relevance to diagnosing risks of hypertension and cardiovascular disease (CVD). In particular, hypertension is the single most prevalent disease in patients presenting with COVID-19. The ability to remotely monitor heart and cardiovascular health using a wearable is fundamental to maintaining global population health in the ensuing post-COVID world.

ATCOR has been able to determine four (4) unique and proprietary heart and arterial health features that have never before been extracted in a medically reliable form from a PPG sensor, and which are directly related to cardiovascular health. Details of these developments will be first presented this week to ATCOR's wearables partner and Google's official Wear OS partner, Mobvoi, as another phase of the Joint Development Agreement (JDA) between the parties has now been successfully completed.

Mobvoi is the largest and only Google-backed official Wear OS partner in the Chinese market as well as ATCOR's partner in commercializing ATCOR's consumer-grade technology in the Chinese wearable market. ATCOR will then present to major consumer and wearable device companies which have requested demonstrations of these results as the Company looks to further commercialize these development efforts.

The fact is that no company has ever been able to achieve these development outcomes, including industry leaders like Apple and Microsoft, further demonstrating the significance of this milestone for ATCOR, the engineering talent in the Company, and the value it will drive for the Company going forward.



Craig Cooper
CEO & Managing Director